BML Capital Management LLC Invests $506,000 in Palvella Therapeutics (NASDAQ:PVLA)

BML Capital Management LLC acquired a new position in shares of Palvella Therapeutics (NASDAQ:PVLA - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 42,130 shares of the company's stock, valued at approximately $506,000. Palvella Therapeutics accounts for approximately 0.3% of BML Capital Management LLC's investment portfolio, making the stock its 18th biggest position. BML Capital Management LLC owned 0.38% of Palvella Therapeutics as of its most recent SEC filing.

Palvella Therapeutics Stock Performance

Shares of PVLA stock traded up $2.83 on Tuesday, reaching $27.99. 132,131 shares of the company were exchanged, compared to its average volume of 52,229. Palvella Therapeutics has a 1 year low of $6.20 and a 1 year high of $28.00. The firm has a 50-day moving average of $16.20. The company has a market cap of $314.08 million, a P/E ratio of -2.31 and a beta of 0.54.

Insider Buying and Selling

In other news, Director George M. Jenkins bought 4,000 shares of Palvella Therapeutics stock in a transaction on Wednesday, December 18th. The stock was acquired at an average price of $12.93 per share, with a total value of $51,720.00. Following the completion of the acquisition, the director now directly owns 180,671 shares of the company's stock, valued at $2,336,076.03. The trade was a 2.26 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 6.39% of the stock is currently owned by insiders.

Remove Ads

Analysts Set New Price Targets

A number of analysts recently issued reports on PVLA shares. Canaccord Genuity Group reissued a "buy" rating and set a $39.00 price target on shares of Palvella Therapeutics in a report on Wednesday, February 26th. Scotiabank began coverage on shares of Palvella Therapeutics in a research note on Friday. They set a "sector outperform" rating and a $50.00 target price on the stock. Cantor Fitzgerald began coverage on Palvella Therapeutics in a research note on Wednesday, December 18th. They issued an "overweight" rating for the company. HC Wainwright reaffirmed a "buy" rating and issued a $38.00 price target on shares of Palvella Therapeutics in a report on Tuesday, February 11th. Finally, TD Cowen began coverage on Palvella Therapeutics in a report on Wednesday, February 5th. They issued a "buy" rating and a $44.00 price objective on the stock. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of "Buy" and an average price target of $42.75.

Palvella Therapeutics Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.